// App-Quantinova.ai

5042 : Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.

Researchers

Presenter

  • Julie N Graff

Principal Investigators

  • Christopher J. Hoimes

  • Winald R. Gerritsen

  • Ulka N. Vaishampayan

  • Tony Elliott

  • Clara Hwang

  • A. J. Ten Tije

  • Aurelius Omlin

  • Raymond S. McDermott

  • Yves Fradet

  • Deepak Kilari

  • Cristiano Ferrario

  • Hiroji Uemura

  • Cuizhen Niu

  • Christian Heinrich Poehlein

  • Ronald De Wit

  • Charles Schloss

  • Johann S. De Bono

  • Emmanuel S. Antonarakis

Medical Centers

  • Knight Cancer Institute, Portland, OR

  • Weill Cornell Medicine, New York, NY

  • Duke Cancer Center, Durham, NC

  • Radboud University Medical Center, Njmegen, Netherlands

  • University of Michigan Cancer Center, Dexter, MI

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Henry Ford Health System, Detroit, MI

  • Erasmus MC, Rotterdam, Netherlands

  • Kantonsspital St Gallen, St Gallen, Switzerland

  • Tallaght University Hospital Dublin Ireland

  • CHU de Québec-Université Laval, Québec City, CANADA

  • Canada.

  • The Medical College of Wisconsin, Milwaukee, WI

  • Jewish General Hospital, Montreal, QC, Canada

  • Yokohama City University Medical Center, Yokohama City, Japan

  • MSD China

  • Beijing, China

  • Merck & Co., Inc., Kenilworth, NJ

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Locations

  • United States

  • Netherlands

  • United Kingdom

  • Switzerland

  • Ireland

  • France

  • Canada

  • Japan

  • China

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Enzalutamide

  • CB-7598

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02787005

  • NCT03834493

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved